Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.59 |
| ▸ | NOS1 | P29475 | 3/20 | 0.59 |
| ▸ | NOS2 | P35228 | 3/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383453 | 1.00 | NOS3 (0.59) | NOS3NOS1NOS2SLC7A5PKM | |
| SCHEMBL43865 | 1.00 | NOS3 (0.59) | NOS3NOS1NOS2SLC7A5PKM | |
| SCHEMBL29379111 | 1.00 | NOS3 (0.59) | NOS3NOS1NOS2SLC7A5PKM | |
| Hydrochloric Acid SCHEMBL28690926 | 0.98 | NOS3 (0.58) | NOS3NOS1NOS2SLC7A5PKM | |
| Hydrochloric Acid SCHEMBL28690928 | 0.98 | NOS3 (0.58) | NOS3NOS1NOS2SLC7A5PKM | |
| Dl-Phenylalanine SCHEMBL23214377 | 0.93 | SLC7A5 (0.71) | NOS3NOS1NOS2SLC7A5PKM | |
| SCHEMBL27464327 | 0.87 | NOS3 (0.48) | NOS3NOS1NOS2SLC7A5PKM | |
| SCHEMBL13971424 | 0.86 | SLC7A5 (0.69) | NOS3NOS1NOS2SLC7A5PKM | |
| SCHEMBL9164980 | 0.86 | SLC7A5 (0.69) | NOS3NOS1NOS2SLC7A5PKM | |
| SCHEMBL5326602 | 0.86 | NOS3 (0.53) | NOS3NOS1NOS2SLC7A5PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BICYCLE TX LTD (GB) | 2025-10-23 | — | — | US | claimed |
| EP-4619043-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | Perspective Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2025128149-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETED COMPOUNDS AND USE THEREOF | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-19 | — | — | WO | claimed |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | VIEWPOINT MOLECULAR TARGETING, INC. (US) | 2025-06-12 | — | — | US | claimed |
| WO-2025094171-A1 | SUPERHYDROPHOBIC COATING | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-05-08 | — | — | WO | claimed |
| US-11904020-B2 | Bicyclic peptide ligands specific for TREM2 | BICYCLETX LIMITED (GB) | 2024-02-20 | — | — | US | claimed |
| EP-4308586-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TREM2 | BicycleTX Limited (GB) | 2024-01-24 | — | — | EP | claimed |
| CN-117337295-A | Bicyclic peptide ligands specific for TREM2 | 拜斯科技术开发有限公司 | 2024-01-02 | — | — | CN | claimed |
| EP-4274839-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| CN-117062826-A | Antiinfective bicyclic peptide ligands | 拜斯科技术开发有限公司 | 2023-11-14 | — | — | CN | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| EP-1442050-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) | 2004-08-04 | — | — | EP | claimed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | claimed |
| EP-0918534-A4 | PEPTIDYL PRODRUGS AND METHODS OF MAKING AND USING THE SAME | UNIV PITTSBURGH (US) | 2001-10-10 | — | — | EP | claimed |
| US-5952294-A | OLIGOPEPTIDE ATTACHED TO AMINO, HYDROXY OR THIOL FUNCTIONS OF THERAPEUTIC AGENT, E.G. ARA-C, TO EXTEND ITS BIOLOGICAL ACTIVE LIVE IN VIVO; CONTROLLING THE KINETICS AND METABOLISM; LEUKEMIA; VIRICIDES; ANTITUMOR/-CARCINOGENIC AGENTS | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-09-14 | — | — | US | claimed |
| EP-0920307-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1999-06-09 | — | — | EP | claimed |
| EP-0918534-A1 | PEPTIDYL PRODRUGS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-06-02 | — | — | EP | claimed |
| WO-1998006386-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | ROCHE DIAGNOSTICS GMBH (DE) | 1998-02-19 | — | — | WO | claimed |
| WO-1998004277-A1 | PEPTIDYL PRODRUGS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1998-02-05 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325672-A1 | ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS | ACE2, SARS1, TMPRSS2 | NOS3 2844/4885NOS1 3151/4885NOS2 2965/4885 |
| US-11904020-B2 | Bicyclic peptide ligands specific for TREM2 | APP, TIMCC, ADM2 | NOS3 1646/4885NOS1 2256/4885NOS2 1048/4885 |
| US-20250186630-A1 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | FAP, FIBP, TPX2 | NOS3 4508/4885NOS1 4533/4885NOS2 4575/4885 |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | NOS3 1175/4885NOS1 548/4885NOS2 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.